Amendments to the claims

1-33 (Cancelled)

34. (New) A process to prepare pharmaceutical tablets containing paroxetine, on a commercial scale, which process comprises the steps of:

a) dry admixing paroxetine and dry excipients in a mixer to form a mixture; or

b) dry admixing paroxetine and dry excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and

c) compressing the mixture into tablets;

provided that the excipients include at least one of: sodium starch glycollate, dicalcium phosphate and magnesium stearate.

35. (New) A process to prepare pharmaceutical tablets containing paroxetine, on a commercial scale, which process comprises the steps of:

a) dry admixing paroxetine and dry excipients in a mixer to form a mixture; or

b) dry admixing paroxetine and dry excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and

c) compressing the mixture into tablets;

provided that the excipients include at least one of: sodium starch glycollate, dicalcium phosphate and magnesium stearate;

and further provided that one of the excipients that is compressed into tablets is not microcrystalline cellulose.

36. (New) A process according to claim 34 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

37. (New) A process according to claim 35 in which the amount of paroxetine in each tablet is selected from: 10 mg, 20 mg, 30 mg, 40 mg and 50 mg, wherein the amount of paroxetine is expressed as the free base.

38. (Previously Presented) A process according to claim 36 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

39. (New) A process according to claim 37 in which the amount of paroxetine in each tablet is about 10 mg, wherein the amount of paroxetine is expressed as the free base.

40. (New) A process according to claim 36 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

41. (New) A process according to claim 37 in which the amount of paroxetine in each tablet is about 20 mg, wherein the amount of paroxetine is expressed as the free base.

42. (New) A process according to claim 36 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

43. (New) A process according to claim 37 in which the amount of paroxetine in each tablet is about 30 mg, wherein the amount of paroxetine is expressed as the free base.

44. (New) A process according to claim 36 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

45. (New) A process according to claim 37 in which the amount of paroxetine in each tablet is about 40 mg, wherein the amount of paroxetine is expressed as the free base.

46. (New) A process according to claim 36 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.

47. (New) A process according to claim 37 in which the amount of paroxetine in each tablet is about 50 mg, wherein the amount of paroxetine is expressed as the free base.